Advertisement

Intrathecal Baclofen Therapy: Assessment and Medical Management

  • Maura McManus
Living reference work entry

Abstract

Intrathecal baclofen therapy has been used in the treatment of generalized spasticity in children since 1996. It has also been noted to help decrease dystonia in this population. It is very important to understand the pathophysiology of these conditions and the range of treatments available. Careful assessment is needed to determine whether someone is a good candidate for intrathecal baclofen therapy. Ideally a multidisciplinary team including the patient and family should work together to create realistic goals for treatment including improving function, comfort, and ease of care. All medical issues need to be understood and followed closely before and after intrathecal pump implantation. A screening trial can be performed but is not necessary prior to pump implantation. Optimizing dose titration and catheter tip positioning can help to maximize treatment effects. Medical and surgical complications have been recognized and need to be worked up and managed efficiently. The benefits of intrathecal baclofen therapy have been widely published and include improvement in comfort and function but most importantly in quality of life.

Keywords

Baclofen Spasticity Dystonia Intrathecal Cerebral palsy 

References

  1. Abbott R (1996) Selective rhizotomy for treatment of childhood spasticity. J Child Neurol 11:S36–S42CrossRefPubMedGoogle Scholar
  2. Abousamra O, Rogers KG, McManus M et al (2016) Evaluation of intrathecal baclofen delivery system malfunction by computed tomography scan. Dev Med Child Neurol 58:409–415CrossRefPubMedGoogle Scholar
  3. Albright AL, Cervi A, Singletary J (1991) Intrathecal baclofen for spasticity in cerebral palsy. JAMA 265:1418–1422CrossRefPubMedGoogle Scholar
  4. Albright AL, Barron WB, Fasick MP et al (1993) Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 270:2475–2477CrossRefPubMedGoogle Scholar
  5. Albright AL, Barry MJ, Fasick MP et al (1995) Effects of continuous intrathecal baclofen infusion and selective dorsal rhizotomy on upper extremity spasticity. Pediatr Neurosurg 23:82–85CrossRefPubMedGoogle Scholar
  6. Albright AL, Barry MJ, Fasick MP et al (1996) Continuous intrathecal baclofen for symptomatic generalized dystonia. Neurosurgery 38:934–939CrossRefPubMedGoogle Scholar
  7. Albright AL, Thompson CS, Minnigh MB (2007) Cerebrospinal fluid baclofen concentrations in patient undergoing continuous intrathecal baclofen therapy. Dev Med Child Neurol 49:423–425CrossRefPubMedGoogle Scholar
  8. Armstrong RW (1992) Intrathecal baclofen and spasticity: what do we know and what do we need to know? Dev Med Child Neurol 34:739–745CrossRefPubMedGoogle Scholar
  9. Armstrong RW, Steinbok P, Cochrane DD et al (1997) Intrathecally administered baclofen for the treatment of children with spasticity of cerebral palsy. J Neurosurg 87:409–414CrossRefPubMedGoogle Scholar
  10. Bayhan I, Sees JP, Nishnianidze T (2016) Infection as a complication of intrathecal baclofen treatment in children with cerebral palsy. J Pediatr Orthop 36:305–309CrossRefPubMedGoogle Scholar
  11. Boster AL, Bennett S, Bilsky G et al (2016a) Best practices for intrathecal baclofen therapy: screening test. Neuromodulation 19:616–622CrossRefPubMedGoogle Scholar
  12. Boster AL, Adair R, Gooch JL et al (2016b) Best practices for intrathecal baclofen therapy: dosing and long term management. Neuromodulation 19:623–631CrossRefPubMedGoogle Scholar
  13. Butler C, Campbell S (2000) Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee review Panel. Dev Med Child Neurol 42:634–645CrossRefPubMedGoogle Scholar
  14. Campbell SK, Almeida GL, Penn RD et al (1995) The effects of intrathecally administered baclofen on function in patients with spasticity. Phys Ther 75:352–362CrossRefPubMedGoogle Scholar
  15. Frost F, Nanninga J, Penn R (1989) Intrathecal baclofen infusion: effects on bladder management programs in patients with myelopathy. Am J Phys Med Rehabil 68:112–115CrossRefPubMedGoogle Scholar
  16. Gans B, Glenn M (1990) In: Glenn M, Whyte J (eds) The practical management of spasticity in children and adults. Lea & Febiger, Philadelphia, pp 1–7Google Scholar
  17. Gerszten PC, Albright AL, Barry MJ (1997) Effect on ambulation of continuous intrathecal baclofen infusion. Pediatr Neurosurg 27:40–44CrossRefPubMedGoogle Scholar
  18. Gerszten PC, Albright AL, Johnstone GF (1998) Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with cerebral palsy. J Neurosurg 88:1009–1013CrossRefPubMedGoogle Scholar
  19. Gormley ME Jr (1999) Management of spasticity in children. Part 2: oral and intrathecal baclofen. J Head Trauma Rehabil 2:207–209CrossRefGoogle Scholar
  20. Grabb PA, Guin-Renfroe S, Meythaler JM (1999) Midthoracic catheter placement for intrathecal baclofen administration in children with quadriplegic spasticity. Neurosurgery 45:833–837CrossRefPubMedGoogle Scholar
  21. Katz RT, Campagnolo DI (1994) Pharmacologic management of spasticity. Phys Med Rehabil State Art Rev 8:473–480Google Scholar
  22. Keenan C, Alexander M, Sung I et al (2000) Intrathecal baclofen for treatment of spasticity in children. Phys Med Rehabil State Art Rev 12:275–283Google Scholar
  23. Keisswetter H, Schober W (1975) Lioresal in the treatment of neurogenic bladder dysfunction. Urol Int 30:63–71CrossRefGoogle Scholar
  24. Krach LE (2001) Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. J Child Neurol 16:31–36CrossRefPubMedGoogle Scholar
  25. Kroin JS (1992) Intrathecal drug administration, present use and future trends. Clin Pharmacokinet 22:319–326CrossRefPubMedGoogle Scholar
  26. Kroin JS, Ali A, York M et al (1993) The distribution of medication along the spinal cord after chronic intrathecal administration. Neurosurgery 33:226–230CrossRefPubMedGoogle Scholar
  27. Lance JW (1980) Symposium synopsis. In: Young RR, Feldman RG, Koella WP (eds) Spasticity: disordered motor control. Symposia Specialists, Miami, pp 485–495Google Scholar
  28. Massagli TL (1991) Spasticity and its management in children. Phys Med Rehabil Clin N Am 2:867–889CrossRefGoogle Scholar
  29. Mathur SN, Chu SK, McCormick Z et al (2014) Long-term intrathecal baclofen:outcomes after more than 10 years of treatment. PM & R 6:506–513CrossRefGoogle Scholar
  30. McCormick ZL, Chu SK, Binler D et al (2016) Intrathecal versus oral baclofen: a matched cohort study of spasticity, pain, sleep, fatigue, and quality of life. PM & R 8:551–562Google Scholar
  31. McMahon M, Pruitt D et al (2015) Cerebral palsy. In: Alexander MA, Matthews D (eds) Pediatric rehabilitation principles and practice. Demos Medical, New York, pp 336–364Google Scholar
  32. Medtronic ITB (2017a) The effects of magnetic resonance imaging (MRI) on SyncroMed II drug infusion systems, Therapy product monograph. Medtronic Inc., MinneapolisGoogle Scholar
  33. Medtronic ITB (2017b) The effects of magnetic resonance imaging (MRI) on SyncroMed II drug infusion systems, Therapy technical note. Medtronic Inc., MinneapolisGoogle Scholar
  34. Meythaler JM, Guin-Renfroe S, Grabb P et al (1999) Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. Arch Phys Med Rehabil 80:13–19CrossRefPubMedGoogle Scholar
  35. Meythaler JM, Guin-Renfroe S, Law C et al (2001) Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents and adults with cerebral palsy. Arch Phys Med Rehabil 82:155–161CrossRefPubMedGoogle Scholar
  36. Miller F (1998) Gait analysis in cerebral palsy. In: Dormans JP, Pellegrino L (eds) Caring for the child with cerebral palsy. Brookes, Baltimore, pp 169–191Google Scholar
  37. Muller H, Zierski J, Dralle D (1988) Pharmacokinetics of intrathecal baclofen in spasticity. In: Muller X, Zierski J, Penn RD (eds) Local-spinal therapy of spasticity. Springer, Berlin, pp 223–226CrossRefGoogle Scholar
  38. Muller-Schwefe G, Penn RD (1989) Physostigmine in the treatment of intrathecal baclofen overdose. Report of three cases. J Neurosurg 71:273–275CrossRefPubMedGoogle Scholar
  39. Nanninga JB, Frost F, Penn R (1989) Effect of intrathecal baclofen on bladder and sphincter control. J Urol 142:101–105CrossRefPubMedGoogle Scholar
  40. Peacock W, Straudt L (1991) Functional outcomes following selective posterior rhizotomy in children with cerebral palsy. J Neurosurg 74:380–385CrossRefPubMedGoogle Scholar
  41. Penn RD, Kroin JS (1984) Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1:1078CrossRefPubMedGoogle Scholar
  42. Penn RD, Savoy SM, Corcos D et al (1989) Intrathecal baclofen for severe spinal spasticity. N Engl J Med 320:1517–1521CrossRefPubMedGoogle Scholar
  43. Pin TM, McCartney L, Lewis J et al (2011) Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review. Dev Med Child Neurol 53:885–895CrossRefPubMedGoogle Scholar
  44. Price GW, Wilkins GP, Turnbull MJ et al (1984) Are baclofen-sensitive GABAb receptors present on primary afferent terminals of the spinal cord? Nature 307:71–74CrossRefPubMedGoogle Scholar
  45. Ried S, Pellegrino L, Albinson-Scull S et al (1998) The management of spasticity. In: Dormans JP, Pellegrino L (eds) Caring for the child with cerebral palsy. Brookes, Baltimore, pp 99–123Google Scholar
  46. Rosenson AS, Ali A, Fordham EW (1990) Indium-111 DTPA flow study to evaluate surgically implanted drug pump delivery system. Clin Nucl Med 15:154–156CrossRefPubMedGoogle Scholar
  47. Sampathkumar P, Scanlon PD, Plevak DJ (1998) Baclofen withdrawal presenting as multi-organ system failure. J Neurosurg 88:562–563CrossRefGoogle Scholar
  48. Saulino M, Ivanho C, McGuire JR et al (2016a) Best practices for intrathecal baclofen therapy: patient selection. Neuromodulation 19:607–615CrossRefPubMedGoogle Scholar
  49. Saulino M, Anderson DJ, Doble J (2016b) Best practices for intrathecal baclofen therapy:troubleshooting. Neuromodulation 19:632–641CrossRefPubMedGoogle Scholar
  50. Yoon YK, Lee KC, Cho HE et al (2017) Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury. Medicine 96(34):e7472CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Nemours Alfred I Dupont Hospital for ChildrenWilmingtonUSA

Section editors and affiliations

  • Freeman Miller
    • 1
  1. 1.AI DuPont Hospital for ChildrenWilmingtonUSA

Personalised recommendations